-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 14, the National Medical Security Administration announced the list of newly added drugs included in the national health insurance catalogue and the commercial insurance innovative drug catalogue. The Class 1 innovative biopharmaceutical fuxinzibimab independently developed by Jinsai Pharmaceutical was included in the catalogue. As the only IL-1beta inhibitor currently covered by national health insurance, this medical insurance has rewritten the treatment logic of gout treatment from “mainly uric acid” in the past to “targeting anti-inflammatory, supplementing with uric acid,” and provides a long-term anti-inflammatory mechanism of “one dose every six months”.
Share
Listen to the news
On November 14, the National Medical Security Administration announced the list of newly added drugs included in the national health insurance catalogue and the commercial insurance innovative drug catalogue. The Class 1 innovative biopharmaceutical fuxinzibimab independently developed by Jinsai Pharmaceutical was included in the catalogue. As the only IL-1beta inhibitor currently covered by national health insurance, this medical insurance has rewritten the treatment logic of gout treatment from “mainly uric acid” in the past to “targeting anti-inflammatory, supplementing with uric acid,” and provides a long-term anti-inflammatory mechanism of “one dose every six months”.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending